CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Gilead Sciences, Inc. (GILD) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Gilead Sciences, Inc. (GILD)

Biological Products, (No Diagnostic Substances) · market cap $187.5B · as of 2026-07-08

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-01 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Gilead Sciences (GILD) is a large-cap biopharmaceutical company (~$161B market cap) with a commercial base anchored in HIV, oncology (Trodelvy, Yescarta), and hepatology, generating $29.4B in 2025 revenue and $8.5B net income. The near-term catalyst setup is dense, spanning multiple Phase 2/3 readouts through early 2027, with two high-importance Phase 3 readouts (Eribulin Mesylate, Sacituzumab Govitecan in breast cancer/SCLC) flagged as impact 9/10 before February 2027. A June 2026 Phase 3 trial recently read out negative, adding near-term headline overhang.
The catalyst path
  • 2026-12-01 (est.)Phase 2 · Sacituzumab Govitecan (SG)imp 7/10
  • 2026-12-15 (est.)Phase 2 · Zimberelimabimp 7/10
  • 2026-12-30 (est.)Phase 2 · Remdesivir (RDV)imp 7/10
  • 2026-12-31 (est.)Phase 2 · Sacituzumab Govitecanimp 7/10
  • 2027-01-01 (est.)Partnershipimp 7/10
  • 2027-01-12 (est.)Phase 3 · Sacituzumab Govitecanimp 9/10
  • 2027-01-15 (est.)Phase 2 · Tilpisertib Fosmecarbilimp 7/10
  • 2027-01-31 (est.)Phase 2 · Anti-OX40 Antibody PF-04518600imp 7/10
Pipeline
AssetPhaseIndication
MTXPhase 3Rheumatoid Arthritis
TrodelvyApprovedTriple-Negative Breast Cancer
LenacapavirPhase 3HIV Prevention
MagrolimabPhase 3Myelodysplastic Syndrome
GS-9451Phase 2Hepatitis C, Chronic
KTE-C19Phase 2Refractory Diffuse Large B Cell Lymphoma
didanosine, ddI (drug)Phase 3HIV Infections
efavirenz (drug)Phase 3HIV Infections
QuemliclustatPhase 2Biliary Tract Carcinoma
Cabotegravir Oral TabletPhase 3HIV Infections
CAB LAPhase 3HIV Infections
EsmololPhase 2Atrial Fibrillation
GS-9451 tabletPhase 2Chronic Genotype 1a or 1b HCV Infection
MVA.HTIPhase 2HIV/AIDS
Sacituzumab Govitecan-Hziy plus bevacizumabPhase 2NSCLC Stage IV
LevocarnitinePhase 2HIV Infections
ChAdOx1.HTIPhase 2HIV/AIDS
GS-9620Phase 2HIV/AIDS
Tenofovir Disoproxil Fumarate + EmtricitabinePhase 3HIV Infections
TDF/FTC tabletsPhase 3HIV Infections
Price & technical context
3-month
+13.4%
6-month
+27.0%
12-month
+30.3%
52-wk range
$118.30–$174.48
vs 50-day MA
+5.7%
vs 200-day MA
+16.6%
Realized vol
27.2%
Max drawdown
-22.0%

Daily closes through 2026-11-19. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for GILD (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.